IOL CHEM AND PHARMA Latest Share Price (IOLCP)
TODAY IN ONE LINE
IOLCP rose 1.8% on above-average volume (2.5x avg), outperforming Nifty's 0.1% move, reaching near its 52-week high of ₹203.0.
With a market cap of ₹5,841.2 Cr., it trades at a P/E of 32.86. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
IOL CHEM AND PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 69.7% YoY
- ●High Promoter HoldingPromoters hold 62.3% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.07x
- ●FII AccumulationFII holding increased by 3.15% QoQ
- ●Promoter BuyingPromoters increased holdings by 4.80% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 7.7%
Latest IOL CHEM AND PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
IOL CHEM AND PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for IOL CHEM AND PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
IOL CHEM AND PHARMA trades at a P/E of 32.86× and P/B of 3.07×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
IOL CHEM AND PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for IOL CHEM AND PHARMA — derived from the latest tape, not yesterday's close.
IOL CHEM AND PHARMA last traded at ₹199.95 with an intraday range of ₹192.5–₹204.98 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹199.95| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 230.75 | +30.80 | +15.40% |
| R3 | 218.27 | +18.32 | +9.16% |
| R2 | 211.62 | +11.67 | +5.84% |
| R1 | 205.79 | +5.84 | +2.92% |
| PIVOT | 199.14 | -0.81 | -0.40% |
| CURRENT | 199.95 | — | — |
| S1 | 193.31 | -6.64 | -3.32% |
| S2 | 186.66 | -13.29 | -6.64% |
| S3 | 180.83 | -19.12 | -9.56% |
| S4 | 168.35 | -31.60 | -15.81% |
IOLCP is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹194.5–₹197.9
Trading Inside opening range
IOL CHEM AND PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for IOL CHEM AND PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
IOL CHEM AND PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,841.2 Cr. and reported EPS of ₹2.20.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,079 | 2,319 ▲ 11.5% |
| Sales Growth YoY %Derived | -2.51% | 11.54% |
| Other Income | 22 | 21 ▼ 4.6% |
| Total Income | 2,102 | 2,340 ▲ 11.4% |
| 1,392 | 1,487 ▲ 6.8% | |
| Gross ProfitDerived | 687 | 832 ▲ 21.0% |
| Gross Margin %Derived | 33.06% | 35.87% |
| 485 | 563 ▲ 16.1% | |
| EBITDA (Operating Profit)Derived | 202 | 269 ▲ 33.0% |
| OPM %Derived | 9.73% | 11.60% |
| 87 | 84 ▼ 3.7% | |
| Profit Before Tax (PBT) | 138 | 184 ▲ 33.6% |
| 37 | 47 ▲ 26.6% | |
| Effective Tax %Derived | 26.74% | 25.34% |
| Total Profit for Period | 101 | 138 ▲ 36.2% |
| Net Profit (Owner's PAT)Derived | 101 | 138 ▲ 36.2% |
| Net Profit Margin %Derived | 4.86% | 5.94% |
| PAT Growth YoY %Derived | -24.82% | 36.18% |
| Earnings Per Share (EPS ₹) | 3.44 | 4.69 ▲ 36.3% |
| Diluted Shares Outstanding (Cr) | 29 | 29 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 3 ▲ 280.6% |
| Total Expenses (incl. D&A & Interest) | 1,964 | 2,156 ▲ 9.8% |
| Material Cost % of RevenueDerived | 65.33% | 64.75% |
| Employee Cost % of RevenueDerived | 10.42% | 10.71% |
| Other Cost % of RevenueDerived | 12.91% | 13.57% |
| Interest Coverage (x)Derived | 8.83x | 12.97x |
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|
| Revenue from Operations | 2,184 | 2,217 ▲ 1.5% | 2,133 ▼ 3.8% | 2,079 ▼ 2.5% | 2,319 ▲ 11.5% | |
| Sales Growth YoY %Derived | — | 1.52% | -3.80% | -2.51% | 11.54% | |
| Other Income | 32 | 26 ▼ 20.1% | 30 ▲ 17.4% | 22 ▼ 25.5% | 21 ▼ 4.6% | |
| Total Income | 2,216 | 2,243 ▲ 1.2% | 2,163 ▼ 3.6% | 2,102 ▼ 2.8% | 2,340 ▲ 11.4% | |
1,571 | 1,547 ▼ 1.5% | 1,397 ▼ 9.7% | 1,392 ▼ 0.4% | 1,487 ▲ 6.8% | ||
| Gross ProfitDerived | 614 | 670 ▲ 9.2% | 736 ▲ 9.8% | 687 ▼ 6.6% | 832 ▲ 21.0% | |
| Gross Margin %Derived | 28.09% | 30.22% | 34.50% | 33.06% | 35.87% | |
355 | 444 ▲ 25.1% | 505 ▲ 13.7% | 485 ▼ 4.0% | 563 ▲ 16.1% | ||
| EBITDA (Operating Profit)Derived | 258 | 226 ▼ 12.6% | 231 ▲ 2.2% | 202 ▼ 12.3% | 269 ▲ 33.0% | |
| OPM %Derived | 11.83% | 10.18% | 10.81% | 9.73% | 11.60% | |
38 | 63 ▲ 66.5% | 79 ▲ 26.2% | 87 ▲ 9.8% | 84 ▼ 3.7% | ||
| Profit Before Tax (PBT) | 225 | 189 ▼ 16.1% | 182 ▼ 3.7% | 138 ▼ 24.1% | 184 ▲ 33.6% | |
57 | 50 ▼ 13.4% | 47 ▼ 4.6% | 37 ▼ 21.9% | 47 ▲ 26.6% | ||
| Effective Tax %Derived | 25.43% | 26.24% | 26.00% | 26.74% | 25.34% | |
| Total Profit for Period | 168 | 139 ▼ 17.0% | 134 ▼ 3.4% | 101 ▼ 24.8% | 138 ▲ 36.2% | |
| Net Profit (Owner's PAT)Derived | 168 | 139 ▼ 17.0% | 134 ▼ 3.4% | 101 ▼ 24.8% | 138 ▲ 36.2% | |
| Net Profit Margin %Derived | 7.68% | 6.28% | 6.30% | 4.86% | 5.94% | |
| PAT Growth YoY %Derived | — | -17.02% | -3.39% | -24.82% | 36.18% | |
| Earnings Per Share (EPS ₹) | 5.71 | 4.74 ▼ 17.0% | 4.58 ▼ 3.4% | 3.44 ▼ 24.9% | 4.69 ▲ 36.3% | |
| Diluted Shares Outstanding (Cr) | 29 | 29 ▲ 0.0% | 29 ▲ 0.0% | 29 ▲ 0.0% | 29 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -0 ▲ 66.7% | -1 ▼ 545.0% | -1 ▼ 11.6% | 3 ▲ 280.6% | |
| Total Expenses (incl. D&A & Interest) | 1,991 | 2,054 ▲ 3.2% | 1,981 ▼ 3.5% | 1,964 ▼ 0.9% | 2,156 ▲ 9.8% | |
| Material Cost % of RevenueDerived | 72.29% | 69.28% | 67.29% | 65.33% | 64.75% | |
| Employee Cost % of RevenueDerived | 6.47% | 7.59% | 9.43% | 10.42% | 10.71% | |
| Other Cost % of RevenueDerived | 9.79% | 12.45% | 14.26% | 12.91% | 13.57% | |
| Interest Coverage (x)Derived | 25.94x | 10.90x | 10.41x | 8.83x | 12.97x |
IOL CHEM AND PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at IOL CHEM AND PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
IOL CHEM AND PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for IOL CHEM AND PHARMA.
Our AI distills the core fundamental drivers supporting IOL CHEM AND PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
IOL CHEM AND PHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding 62.28% ensures aligned long-term strategic vision and governance.
Latest quarterly EPS grew 69.2% YoY despite competitive pressures in commoditized APIs.
TTM revenue growth 17.4% outpaces peer average, signaling robust market traction.
Low debt-to-equity ratio 0.0007x provides substantial financial flexibility for growth.
Operating cash flow ₹214.42 Cr consistently exceeds net profit, indicating quality earnings.
Key Risks.
Operating margin 8.58% significantly lags peer average 16–33%, indicating weak pricing power.
ROE 7.65% and ROCE 8.01% trail peer benchmarks substantially, signaling poor capital efficiency.
P/E 31.30x elevated relative to peer median, limiting valuation appeal despite growth.
Dividend yield 0.53% modest, limiting appeal for income-focused investors seeking returns.
FII holdings eased from 3.54% to 1.47%, signaling weak foreign institutional investor conviction.
Flip Conditions.
Valuation risk. a P/E above 43 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.25%.
IOL CHEM AND PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — IOL CHEM AND PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
IOL CHEM AND PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for IOL CHEM AND PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
IOL CHEM AND PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for IOL CHEM AND PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in IOL CHEM AND PHARMA stood at 27.6% of traded volume, against a 20-day average of 36.2%.
IOL CHEM AND PHARMA announcements: results, concalls, ratings, M&A.
Filings IOL CHEM AND PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
IOL CHEM AND PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 107 documents below.
Shareholders meeting
Submission of Voting Results along with Scrutinizer s Report with regard to the 39th Annual General Meeting of the Company
Shareholders meeting
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 02, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
IOL CHEM AND PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue IOL CHEM AND PHARMA has declared, sequenced by announce and record date.
IOL CHEM AND PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
IOL CHEM AND PHARMA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in IOL CHEM AND PHARMA as reported to SEBI — buying and selling signals from the people who know the business best.
IOL CHEM AND PHARMA insider activity below tracks 20 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 18 Mar 2026 | buy | +7.00 L | ₹5.14 Cr. | ₹73.44 |
| Mayadevi Polycot Limited | Insider | 18 Mar 2026 | buy | +54.2 K | ₹40 L | ₹73.81 |
| NCVI Enterprises Limited | Insider | 18 Mar 2026 | buy | +7.00 L | ₹5.14 Cr. | ₹73.44 |
| Mayadevi Polycot Limited | Insider | 18 Mar 2026 | buy | +54.2 K | ₹40 L | ₹73.81 |
| NCVI Enterprises Limited | Insider | 18 Mar 2026 | buy | +7.00 L | ₹5.14 Cr. | ₹73.44 |
| Mayadevi Polycot Limited | Insider | 18 Mar 2026 | buy | +54.2 K | ₹40 L | ₹73.81 |
About IOL CHEM AND PHARMA: business, sector, key facts.
What IOL CHEM AND PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
IOL CHEM AND PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: IOLCP, BSE: 524164.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) is a prominent Indian company engaged in the manufacturing and sale of pharmaceutical and chemical products both domestically and globally. Their core business revolves around the production and distribution of a wide range of Active Pharmaceutical Ingredients (APIs).
A significant portion of IOLCP's API portfolio focuses on ingredients used in various therapeutic areas. This includes APIs for anti-inflammatory, analgesic and antipyretic treatments (like ibuprofen lysinate and ibuprofen sodium), anti-diabetic medications (metformin), anti-platelet agents (clopidogrel bisulphate), cholesterol-lowering drugs (fenofibrate), anti-convulsants (lamotrigine, gabapentin, levetiracetam), and proton pump inhibitors (pantoprazole). The company also produces paracetamol, a common analgesic and antipyretic.
Beyond pharmaceuticals, IOLCP demonstrates a strong presence in the specialty industrial chemicals market. They supply a diverse array of products including ethyl acetate, isobutyl benzene, acetyl chloride, para-aminophenol, and monochloroacetic acid. These chemicals find applications across a wide spectrum of industries, such as food processing, flexible packaging, pharmaceuticals, textiles, ink and paint manufacturing, pesticide production, and the creation of chemical intermediates. This diversification allows IOLCP to cater to multiple sectors and reduces reliance on any single market.
Established in 1986 and headquartered in Ludhiana, India, IOLCP has a long history of operation within the chemical and pharmaceutical sectors. Their success is built on the foundation of providing high-quality APIs and specialty chemicals, contributing significantly to various industries both within India and internationally. The company's broad product range and diversified customer base solidify its position as a key player in the market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about IOL CHEM AND PHARMA (IOLCP).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of IOL CHEM AND PHARMA (IOLCP)?
The current share price of IOL CHEM AND PHARMA (IOLCP) is ₹199.95. Today, the stock has gained by ₹3.52 (1.79%), trading in a range of ₹192.50 to ₹204.98. The stock opened at ₹197.00 with a trading volume of 52,91,531 shares.
02Is IOL CHEM AND PHARMA stock a good investment for long-term?
IOL CHEM AND PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,841.2 Cr., P/E ratio of 32.86, ROE of 7.65%, and ROCE of 7.96%. The dividend yield stands at 0.5%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of IOL CHEM AND PHARMA stock?
The 52-week high price of IOL CHEM AND PHARMA (IOLCP) is ₹202.99, while the 52-week low is ₹67.19. Currently trading at ₹199.95, the stock is 197.59% above its 52-week low and 1.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy IOL CHEM AND PHARMA stock at the current price?
Whether to buy IOL CHEM AND PHARMA stock at ₹199.95 depends on multiple factors. The stock is currently trading with a P/E ratio of 32.86 and P/B ratio of 3.07. Today's performance shows a gain of 1.79%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of IOL CHEM AND PHARMA and when is the next dividend?
IOL CHEM AND PHARMA offers a dividend yield of 0.5%, which means for every ₹100 invested at the current price of ₹199.95, you can expect to receive approximately ₹0.50 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of IOL CHEM AND PHARMA?
IOL CHEM AND PHARMA's key financial metrics include: P/E Ratio: 32.86, P/B Ratio: 3.07, ROE: 7.65%, ROCE: 7.96%, Dividend Yield: 0.5%, EPS: ₹2.20, Book Value: ₹61.27, and Debt-to-Equity: 0.07. The company's market cap stands at ₹5,841.2 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is IOL CHEM AND PHARMA stock performing today in the market?
IOL CHEM AND PHARMA stock opened at ₹197.00 and is currently trading at ₹199.95, showing a gain of ₹3.52 (1.79%). The intraday high is ₹204.98 and low is ₹192.50. The trading volume stands at 52,91,531 shares, indicating strong market participation today.
08What is the P/E ratio of IOL CHEM AND PHARMA and what does it indicate?
IOL CHEM AND PHARMA has a Price-to-Earnings (P/E) ratio of 32.86, which means investors are willing to pay 32.86 for every ₹1 of earnings. With an EPS of ₹2.20, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about IOL CHEM AND PHARMA (IOLCP) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.